RT Journal Article
SR Electronic
T1 Azithromycin Treatment Response as a Probe to Attribute Bacterial Aetiologies of Diarrhoea using Molecular Diagnostics: A Reanalysis of the AntiBiotics for Children with severe Diarrhoea (ABCD) Trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.03.24312730
DO 10.1101/2024.09.03.24312730
A1 Cornick, Jennifer
A1 Elwood, Sarah
A1 Platts-Mills, James
A1 Pavlinac, Patricia
A1 Manji, Karim
A1 Sudfeld, Chris
A1 Duggan, Christopher P.
A1 Dube, Queen
A1 Bar-Zeev, Naor
A1 Kotloff, Karen
A1 Sow, Samba O
A1 Sazawal, Sunil
A1 Singa, Benson O
A1 Walson, Judd L
A1 Qamar, Farah
A1 Ahmed, Tahmeed
A1 Costa, Ayesha De
A1 Rogawski McQuade, Elizabeth T
YR 2024
UL http://medrxiv.org/content/early/2024/09/04/2024.09.03.24312730.abstract
AB Background Multi-pathogen molecular diagnostics enable assignment of diarrhoea aetiology, but defining thresholds of pathogen quantity to accurately attribute aetiology is challenging in high-burden settings where coinfections are common. The Antibiotics for Children with severe Diarrhoea (ABCD) trial provides an opportunity to leverage the azithromycin treatment response to inform which diarrhoea episodes are bacterial.Methods We analysed data from ABCD, which randomized children with watery diarrhoea to azithromycin or placebo. We quantified heterogeneity in the azithromycin treatment response by the quantity of enteric pathogens detected by qPCR as a tool for understanding aetiology.Results The heterogeneity in azithromycin treatment response was most prominent for Shigella. The risk ratio for diarrhoea on day 3 post enrolment for azithromycin compared to placebo was 13% (95% CI:3, 23) lower per log10 increase in Shigella quantity. The protective effect of azithromycin on diarrhoea at day 3 also became stronger as pathogen quantities increased for Vibrio cholerae, ST-ETEC, and tEPEC. No association between pathogen quantity and azithromycin response was observed for Campylobacter, LT-ETEC or EAEC. The associations were consistent for the outcome of 90-day hospitalisation or death.Conclusions The relationships between response to azithromycin treatment and bacterial pathogen quantities observed for Shigella, Vibrio cholerae, ST-ETEC and tEPEC confirm prior evidence that these pathogens are the likely cause of diarrhoea when detected at high quantities. The lack of a similar response pattern for Campylobacter, LT-ETEC or EAEC is consistent with the limited association between pathogen quantity and diarrhoea symptoms previously observed in large studies of diarrhoea aetiology.Key message (3 succinct bullet points, each a single sentence)We investigated whether heterogeneity in treatment response observed in the ABCD trial, where children with diarrhoea were randomised to receive azithromycin or placebo, could be used to inform aetiological attribution of diarrhoea to bacterial enteric pathogens.The protective effect of azithromycin on diarrhoea at day 3 and hospitalisation or death at day 90 became stronger as pathogen quantities increased for Shigella, Vibrio cholerae, ST-ETEC and tEPEC but not for Campylobacter, LT-ETEC or EAEC.The relationships between Shigella, Vibrio cholerae, ST-ETEC and tEPEC quantity and response to antibiotic treatment confirm prior evidence that these pathogens are the likely cause of diarrhoea when detected at high quantities and could be used to inform which diarrhoea cases should be treated with antibiotics.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03130114Clinical Protocols https://cdn.clinicaltrials.gov/large-docs/14/NCT03130114/Prot_001.pdf Funding StatementThis study was funded by the Bill & Melinda Gates Foundation (grant numbers OPP 1126331 and OPP 1179069). This study was funded by the Bill & Melinda Gates Foundation (INV-044317 to ETRM).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics approval was obtained from the World Health Organization Ethics Review Committee, Emory University, and from the participating countries.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.